Showing results (1-10 of 76) with videos related to
Sort By:
Pageof 8
Cancer Chemotherapy and Pharmacology|March 15, 2019
Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancerRoger M Phillips, Paul M Loadman, Guru ReddyBiochimica Et Biophysica Acta. Reviews on Cancer|October 25, 2021
Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?Francis M Barnieh, Paul M Loadman, Robert A FalconerCurrent Research in Pharmacology and Drug Discovery|December 15, 2021
Progress towards a clinically-successful ATR inhibitor for cancer therapyFrancis M Barnieh, Paul M Loadman, Robert A FalconerDrug Discovery Today|November 24, 2020
How can the potential of the duocarmycins be unlocked for cancer therapy?Zoë Jukes, Goreti Ribeiro Morais, Paul M Loadman, et al.Neoplasia (New York, N.Y.)|August 7, 2010
Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cellsGillian Hawcroft, Paul M Loadman, Andrea Belluzzi, et al.Journal of Pharmacological and Toxicological Methods|May 10, 2011
Use of matrix-assisted laser desorption/ionisation mass spectrometry in cancer researchHannah Bateson, Saira Saleem, Paul M Loadman, et al.European Journal of Cancer (Oxford, England : 1990)|May 5, 2005
Formation of DNA interstrand cross-links as a marker of Mitomycin C bioreductive activation and chemosensitivityMilène Volpato, Jill Seargent, Paul M Loadman, et al.Advanced Drug Delivery Reviews|January 13, 2016
Proteases in cancer drug deliveryJennifer Vandooren, Ghislain Opdenakker, Paul M Loadman, et al.Critical Reviews in Oncology/Hematology|July 15, 2019
Precision pharmacology: Mass spectrometry imaging and pharmacokinetic drug resistanceMaria Jove, Jade Spencer, Malcolm Clench, et al.Carbohydrate Polymers|September 2, 2019
Recent advances in the analysis of polysialic acid from complex biological systemsXiaoxiao Guo, Sara M Elkashef, Paul M Loadman, et al.Pageof 8